IRS-1: Auditing the effectiveness of mTOR inhibitors
- 31 March 2006
- journal article
- review article
- Published by Elsevier BV in Cancer Cell
- Vol. 9 (3), 153-155
- https://doi.org/10.1016/j.ccr.2006.02.027
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Mutations in the PI3K/PTEN/TSC2 Pathway Contribute to Mammalian Target of Rapamycin Activity and Increased Translation under Hypoxic ConditionsCancer Research, 2006
- mTOR and S6K1 Mediate Assembly of the Translation Preinitiation Complex through Dynamic Protein Interchange and Ordered Phosphorylation EventsCell, 2005
- The Akt-mTOR tango and its relevance to cancerCancer Cell, 2005
- Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complexGenes & Development, 2004
- The tor pathway: a target for cancer therapyNature Reviews Cancer, 2004
- Phosphatidylinositol 3-Kinase/Akt Pathway Regulates Tuberous Sclerosis Tumor Suppressor Complex by Phosphorylation of TuberinJournal of Biological Chemistry, 2002
- TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signallingNature, 2002
- A Rapamycin-Sensitive Pathway Down-Regulates Insulin Signaling via Phosphorylation and Proteasomal Degradation of Insulin Receptor Substrate-1Molecular Endocrinology, 2000
- Translational Homeostasis: Eukaryotic Translation Initiation Factor 4E Control of 4E-Binding Protein 1 and p70 S6 Kinase ActivitiesMolecular and Cellular Biology, 1999
- A Signaling Pathway to Translational ControlCell, 1996